Shambhavi Borde
Immunology and Microbiology · Purdue University West Lafayette
Publications
13
Citations
139
Est. group size
~1
Recurring co-author estimate
Active years
9
Publishing since 2018
Shambhavi Borde's research focuses on engineering natural killer (NK) cells, including those derived from induced pluripotent stem cells (iPSCs), to improve cancer immunotherapy for solid tumors like glioblastoma and blood cancers like myeloma. Recent work explores metabolic reprogramming of NK cells and targeting immune checkpoint molecules (like CD73 and TIGIT) to help these engineered cells work better against tumors. Earlier work in this record focused on a different area: pharmaceutical formulation science, particularly the development of amorphous solid dispersions to improve drug solubility, including for tuberculosis treatment.
Publication output has been modest and variable over the past decade, with a shift from pharmaceutical formulation topics (2018-2021) to NK cell immunotherapy research (2022-2026), averaging about 1.6 publications per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- SLC1A5 augmentation bypasses NK cell transduction barriers to deliver complex CAR payloads
The Journal of Immunology · 2026
- 196 Targeting the CD73 immune checkpoint for NK cell-based therapy for myeloma
Regular and Young Investigator Award Abstracts · 2025
- 306 Selective immunometabolic reprogramming of NK cells to enhance their metabolic fitness against glioblastoma
Regular and Young Investigator Award Abstracts · 2025
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
Nature Communications · 2024
- Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities
Trends in Pharmacological Sciences · 2023
- 1206 Immunometabolic modulation of engineered iPSC-NK cells for immunotherapy of solid tumors
Regular and Young Investigator Award Abstracts · 2023
- Solid Dosage Forms: Formulation and Characterization
2022
- 319 Immunometabolic modulation of engineered iPSC-NK cells for immunotherapy of solid tumors
Regular and Young Investigator Award Abstracts · 2022
- Ternary solid dispersions: classification and formulation considerations
Drug Development and Industrial Pharmacy · 2021
- Formulation and characterization of ternary amorphous solid dispersions of a highly potent anti-tubercular agent and curcumin
Journal of Drug Delivery Science and Technology · 2021
- Investigating crystallization tendency, miscibility, and molecular interactions of drug–polymer systems for the development of amorphous solid dispersions
Drug Development and Industrial Pharmacy · 2021
- Development of Amorphous Ternary Solid Dispersions of a Novel Anti-Tubercular Indole-2-Carboxamide Derivative with Curcumin/Clofazimine for Tuberculosis Treatment
2019
- Solid Dosage Forms: Formulation and Characterization
2018
- Regular and Young Investigator Award Abstracts×4
- Drug Development and Industrial Pharmacy×2
- Nature Communications×1
- Trends in Pharmacological Sciences×1
- Journal of Drug Delivery Science and Technology×1
- Sandro Matosevic
Immunology and Microbiology · Purdue University West Lafayette
- Kyle B. Lupo
Immunology and Microbiology · Purdue University West Lafayette
- Dean A. Lee
Immunology and Microbiology · The Ohio State University
- Jilu Zhang
Immunology and Microbiology · Indiana University
- Jianhua Yu
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile